Next Arc Research

Not logged in? You're viewing the Free tier. Join for free or log in to access your membership content.
Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.
Disclosure: The author does not hold a position in RXRX.
← Back to Free Index

RXRX

Analysis as of: 2026-10-14
Recursion Pharmaceuticals, Inc.
Clinical-stage biotech using AI, automation, and proprietary experimental data to discover and develop internal and partnered medicines.
ai automation biotech healthcare software
On Yahoo Finance ...
Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

Clinical proof is the gating rerating event
The platform has real technical substance, but the five-year upside depends on converting that engine into approval-shaped assets and durable partner economics. Near-term repricing is concentrated in one lead rare-disease readout and its regulatory follow-through.

Analysis

Thesis
Recursion can grow from a speculative AI-biotech story into a validated platform-biotech if REC-4881 earns an approval-shaped path and the company converts its proprietary data, automated labs, and partner workflows into repeatable milestone, royalty, and owned-asset economics before financing becomes the dominant narrative.
Last Economy Alignment
This is not a thin software wrapper: value sits in proprietary biology data, wet-lab throughput, and drug assets, so cheaper cognition should help. The score stops short of very high because clinical proof and partner bargaining still decide how much value shareholders keep.
Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple
3.6x (from 5 most recent analyses)
Reasoning
The upside case is a business-model upgrade, not just more experiments. If the lead rare-disease program gets a workable regulatory path and at least one more internal or partnered program validates the engine, investors can value the company as a real platform-biotech with owned assets, milestones, and royalties rather than as a cash-burning discovery vendor. I stop short of hypergrowth because proof still runs through clinical and financing gates.
Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary
The core risk is proof conversion, not AI demo quality. Recursion has a credible data-and-automation stack, but shareholder value still depends on translating that stack into approval-shaped clinical outcomes and durable partner economics before financing needs force a weaker bargaining position.
Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Last Economy Structure

AI Industrial Score
0.42
They own a large biology dataset, automated labs, and the workflow that turns experiments into drug ideas, so cheaper AI should help them compound faster than software-only peers. The catch is that shareholders only win if lead drugs and partner programs produce real clinical proof before cash needs force dilution.
Upgrade to Reader to also access: Score Decomposition, Confidence Level
Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility
Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target
$7.22
Upgrade to Reader to also access: Bull Case, Base Case, Bear Case